-
Gap19: From Cx43 Biology to Assay Strategy
2026-09-16
Gap19 is a selective connexin 43 hemichannel blocker that connects channel biology with neuroinflammatory assay design. This article interprets macrophage NF-κB findings alongside astrocyte and cerebral ischemia evidence to clarify what the peptide can—and cannot—establish experimentally.
-
LY2886721: Practical BACE Inhibitor Workflows
2026-09-15
LY2886721 supports controlled BACE1 enzyme inhibition across biochemical, neuronal, and translational Alzheimer’s disease research workflows. Its strongest use-case is not simply maximal amyloid beta reduction, but measuring how graded pathway suppression affects APP processing, secreted biomarkers, and synaptic function.
-
Amyloid β-Peptide (1-42) (human): Lab Guide
2026-09-15
A practical, evidence-based guide to using Amyloid β-Peptide (1-42) (human), SKU B6057, in neuronal viability, microglial uptake, and ion-channel experiments. It connects product handling specifications with published Aβ1–42 biology to improve assay interpretation, preparation consistency, and vendor selection.
-
YM 58483 (BTP2) SOCE Research Workflows
2026-09-14
YM 58483 (BTP2) gives researchers a practical way to test whether store-operated Ca2+ entry drives immune activation or fibrosis-associated signaling. This workflow-focused guide covers concentration planning, calcium and NFAT readouts, salivary-gland fibrosis models, and troubleshooting for interpretable SOCE blockade.
-
Reparixin and the IL-8–CXCR1 Translational Axis
2026-09-14
A mechanistic and translational framework for using Reparixin, a CXCR1/2 inhibitor, to interrogate IL-8 signaling across neutrophil biology, tissue injury, and microbial oncology.
-
HMGCS2, Lyso-PC, and Pulmonary Fibrosis
2026-09-13
Yang et al. identify injured alveolar type II epithelial cells as a major source of lipid accumulation in bleomycin-associated pulmonary fibrosis and show that released lysophosphatidylcholines activate lung fibroblasts. Their mechanistic data connect reduced epithelial HMGCS2 to impaired lipid degradation through a PPARα–CPT1A/CPT2 axis, providing a framework for studying epithelial–fibroblast crosstalk and lipid-mediated fibrosis.
-
LL-37, KE-18, and KR-12: Selective Biofilm Activity
2026-09-12
Luo and colleagues compared LL-37 with the truncated mimetics KE-18 and KR-12, showing that planktonic killing and biofilm control are not interchangeable peptide activities. The study provides a useful framework for selecting KR-12 human antimicrobial peptide assays while emphasizing that activity depends on organism, biofilm stage, and experimental endpoint.
-
CTCF, Centromere Function, and Mitotic Fidelity
2026-09-11
This study uses rapid, inducible CTCF degradation to show that CTCF maintains centromere architecture rather than primarily recruiting CENP-E to kinetochores. The findings connect CTCF loss with disorganized metaphase alignment, increased intercentromere distance, mitotic failure, and abnormal post-mitotic nuclear shape.
-
Reprogramming Myeloma Immunity with Lenalidomide
2026-09-11
Lenalidomide (CC-5013) is more than a cytotoxicity tool: its immunomodulatory activity can be interpreted through an epigenetic–innate immune framework. Recent DOT1L research shows how mechanistic combination assays may improve multiple myeloma research, biomarker development, and translational decision-making.
-
EGF Signaling as a Translational Assay Lever
2026-09-10
Recombinant human EGF is more than a routine culture supplement: it is a defined biological input that can improve assay interpretability across epithelial, stemness, repair, and oncology models. This article connects EGF receptor biology with the MYC–EphA2 synthetic-lethal findings reported in a recent breast cancer study, while defining practical controls, product-selection criteria, and the boundaries of translational inference.
-
4-Phenylbutyric acid in Reliable ER Stress Assays
2026-09-10
This scenario-driven guide explains how 4-Phenylbutyric acid (SKU C6831) can help researchers interpret ER-stress-linked changes in viability, proliferation, apoptosis, and ferroptosis assays. It combines practical formulation guidance with quantitative findings from a recent HK-2 kidney injury study and emphasizes controls, documentation, and reproducibility.
-
1-myristoylglycerophosphocholine in Fibrosis Assays
2026-09-09
Use 1-myristoylglycerophosphocholine, also known as 14:0 Lyso-PC, as a defined lysophospholipid challenge for separating epithelial lipid remodeling from fibroblast activation. This workflow combines conditioned-medium experiments, direct lipid exposure, lipid signaling pathway analysis, and formulation controls for more interpretable fibrosis and smooth muscle studies.
-
Amyloid Beta-Peptide (1-40): Applied Workflows
2026-09-09
Build controlled Aβ40 experiments spanning aggregation, membrane interaction, neurotoxicity, and microglial signaling. This guide emphasizes peptide-state control, quantitative assay design, and troubleshooting for reproducible Alzheimer’s disease research.
-
GDF11, Smad2/3, and Antioxidant Aging Biology
2026-09-08
This 2022 Biogerontology study reports that orally delivered, yeast-surface-displayed recombinant GDF11 delayed several aging biomarkers in male mice and enhanced antioxidant defenses through Smad2/3 signaling. Its main practical contribution is a delivery and mechanism framework that connects GDF11 bioavailability with oxidative-stress control, while leaving important questions about sex, species, receptor specificity, and causality for future studies.
-
Amyloid Beta-Peptide (1-40) Workflow Guide
2026-09-08
Build reproducible Aβ40 aggregation, imaging, and neurotoxicity workflows with a defined synthetic peptide and controlled preparation history. Translate the reference study’s ratiometric fibril-detection strategy into practical assay controls, isoform comparisons, and troubleshooting decisions.